TF and metabolic dysfunction-associated steatohepatitis: Mice were treated with either DMSO 0.8% (control group) or with the R-Tf-D-LP4 peptide 14 mg/kg (Figure 1A) starting from week six after birth for steatosis, or at week eight for NASH.